Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 4/20 | 0.61 |
| ▸ | CDK9 | P50750 | 4/20 | 0.61 |
| ▸ | CDK2 | P24941 | 2/20 | 0.59 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.59 |
| ▸ | CDK4 | P11802 | 1/20 | 0.59 |
| ▸ | CCND1 | P24385 | 1/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 4/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | GSK3A | P49840 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29383914 | 1.00 | CCNT1 (0.61) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL7195024 | 0.89 | CCNT1 (0.76) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL6575073 | 0.82 | SIRT2 (0.49) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL7815802 | 0.82 | CCNT1 (0.66) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL29419482 | 0.82 | CCNT1 (0.61) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL7508106 | 0.82 | CCNT1 (0.61) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL6949072 | 0.82 | GSK3B (0.68) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL29349877 | 0.82 | GSK3B (0.68) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL7195040 | 0.81 | CCNT1 (0.40) | CCNT1CDK9CDK2CCNE2CDK4 | |
| SCHEMBL29386790 | 0.81 | CCNT1 (0.60) | CCNT1CDK9CDK2CCNE2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307447-B1 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | HOFFMANN LA ROCHE (CH) | 2004-12-15 | — | — | EP | disclosed |
| US-6589977-B1 | Bisindolylpyrrole derivatives represented by general formula (I) which are useful in inhibiting cell death and expected as being useful as preventives and remedies for the progress of various diseases in the progress and worsening of which cell | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2003-07-08 | — | — | US | disclosed |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GONG LEYI (US) | 2002-12-12 | — | — | US | disclosed |
| US-6479490-B2 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| EP-1224932-A1 | DRUGS INHIBITING CELL DEATH | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2002-07-24 | — | — | EP | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
| EP-0397060-B1 | Maleinimide derivatives and their use as medicines | GOEDECKE AG (DE) | 2001-11-21 | — | — | EP | disclosed |
| EP-1152002-A1 | PYRROLE DERIVATIVES AND CELL DEATH INHIBITORS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2001-11-07 | — | — | EP | disclosed |
| EP-1057484-A1 | CELL DEATH INHIBITORS | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2000-12-06 | — | — | EP | disclosed |
| US-5516915-A | Bis-(1H-indol-3-yl)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1996-05-14 | — | — | US | disclosed |
| US-5380746-A | Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1995-01-10 | — | — | US | disclosed |
| EP-0397060-A2 | Maleinimide derivatives and their use as medicines | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | CCNT1 1311/4885CDK9 478/4885CDK2 102/4885 |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | CCNT1 1642/4885CDK9 541/4885CDK2 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.